Next Article in Journal
Genetic and Hormonal Regulation of Chlorophyll Degradation during Maturation of Seeds with Green Embryos
Next Article in Special Issue
Deciphering the Role of B Cells in Multiple Sclerosis—Towards Specific Targeting of Pathogenic Function
Previous Article in Journal
The Semi-Synthetic Peptide Lin-SB056-1 in Combination with EDTA Exerts Strong Antimicrobial and Antibiofilm Activity against Pseudomonas aeruginosa in Conditions Mimicking Cystic Fibrosis Sputum
Previous Article in Special Issue
The Role of ERK Signaling in Experimental Autoimmune Encephalomyelitis
Article Menu
Issue 9 (September) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2017, 18(9), 1992;

Monoclonal Antibodies in Preclinical EAE Models of Multiple Sclerosis: A Systematic Review

Institute of Clinical Pharmacology, University Hospital Frankfurt, 60590 Frankfurt, Germany
Author to whom correspondence should be addressed.
Received: 30 August 2017 / Revised: 12 September 2017 / Accepted: 13 September 2017 / Published: 16 September 2017
(This article belongs to the Special Issue Advances in Multiple Sclerosis 2017)
Full-Text   |   PDF [5668 KB, uploaded 16 September 2017]   |  


Monoclonal antibodies (mAb) are promising therapeutics in multiple sclerosis and multiple new candidates have been developed, hence increasing the need for some agreement for preclinical mAb studies. We systematically analyzed publications of experimental autoimmune encephalomyelitis (EAE) studies showing effects of monoclonal antibodies. A PubMed search retrieved 570 records, out of which 122 studies with 253 experiments were eligible based on experimental design, number of animals and presentation of time courses of EAE scores. Analysis of EAE models, treatment schedules, single and total doses, routes of administration, and onset of treatment from pre-immunization up to 35 days after immunization revealed high heterogeneity. Total doses ranged from 0.1 to 360 mg/kg for observation times of up to 35 days after immunization. About half of experiments (142/253) used total doses of 10–70 mg/kg. Employing this range, we tested anti-Itga4 as a reference mAb at varying schedules and got no, mild or substantial EAE-score reductions, depending on the mouse strain and onset of the treatment. The result agrees with the range of outcomes achieved in 10 reported anti-Itga4 experiments. Studies comparing low and high doses of various mAbs or early vs. late onset of treatment did not reveal dose-effect or timing-effect associations, with a tendency towards better outcomes with preventive treatments starting within the first week after immunization. The systematic comparison allows for extraction of some “common” design characteristics, which may be helpful to further assess the efficacy of mAbs and role of specific targets in preclinical models of multiple sclerosis. View Full-Text
Keywords: autoimmune encephalomyelitis; monoclonal antibody; immune system; multiple sclerosis autoimmune encephalomyelitis; monoclonal antibody; immune system; multiple sclerosis

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Supplementary material


Share & Cite This Article

MDPI and ACS Style

Schmitz, K.; Geisslinger, G.; Tegeder, I. Monoclonal Antibodies in Preclinical EAE Models of Multiple Sclerosis: A Systematic Review. Int. J. Mol. Sci. 2017, 18, 1992.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top